Filgrastim [300 mcg/0.9 mL solution (IV, SC), 0.9 mL pre-filled syringe] for treatment of neutropenia in patients undergoing bone marrow transplantation and patients receiving myelosuppressive cancer chemotherapy
Minor Inclusion | DrugsHTA Council Recommendation (as of 12 January 2023)
As final recommendation, the HTA Council recommends the inclusion of filgrastim [300 mcg/0.9 mL solution (IV, SC), 0.9 mL pre-filled syringe] for treatment of neutropenia in patients undergoing bone marrow transplantation and patients receiving myelosuppressive cancer chemotherapy in the Philippine National Formulary (PNF).
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal/ External Assessment
- Policy Question: Should filgrastim [300 mcg/0.9 mL solution (IV, SC), 0.9 mL pre-filled syringe] for treatment of neutropenia in patients undergoing bone marrow transplantation and patients receiving myelosuppressive cancer chemotherapy be included in the Philippine National Formulary?
- Secretary of Health Decision: Approved as of 01 February 2023
Evidence and Relevant Documents